Agios Pharmaceuticals

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Agios Pharmaceuticals, Inc.
Industry Pharmaceuticals
Founded 2008 (2008)
Headquarters Cambridge, Massachusetts, United States
Key people
David Schenkein (CEO)
Footnotes / references

Agios Pharmaceuticals is a public American pharmaceutical company focused on developing small-molecule anti-cancer therapeutics targeting cancer cell metabolism via the growth factor pathway.[1][2] Among the proteins under investigation by the company are IDH1 and IDH2.[3] The company was founded in 2008 (or 2007)[3] by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts.[1][4] The company tendered an initial public offering in July 2013.[5]:Table 1

In 2012, Agios was named among the defendants in a lawsuit against one of its founders, Craig Thompson, alleging that Thompson used research illegally taken from the Abramson Family Cancer Research Institute in research at Agios.[3]

In May 2016, the company announced it would launch partnership with Celgene, developing metabolic immuno-oncology therapies. The deal could net more than $1 billion for Agios.[6]

In April 2017, the company raised $250 million in a new stock offering in anticipation of FDA approval for its first cancer drug.[7]

Corporate governance[edit]

As of April 2017, Agios' CEO was David Schenkein.[7]

Agios was established as a private company and converted to a public company with its initial public offering in July 2013 and subsequent listing on NASDAQ.[3][5]


  1. ^ a b c Pfeffer, Cary G. (2012). "The biotechnology sector". In Burns, Lawton R. The Business of Healthcare Innovation (Google eBook). Cambridge, United Kingdom: Cambridge University Press. pp. 224, 228. ISBN 9781107024977. 
  2. ^ Anton, Ted (2013). "Chapter 13". The Longevity Seekers (Google eBook). University of Chicago Press. p. 163. ISBN 9780226020938. 
  3. ^ a b c d Pollack, Andrew (February 5, 2012). "Sloan-Kettering Chief Is Accused of Taking Research". The New York Times. open access publication – free to read
  4. ^ "AGIOS PHARMACEUTICALS, INC.". EDGAR. Form 10-K. U.S. Securities and Exchange Commission. March 18, 2014. Commission File Number:001-36014. 
  5. ^ a b Huggett, Brady (December 2013). "Burning Bright". Nat. Biotechnol. 31 (12). pp. 1068–71. open access publication – free to read
  6. ^ "Celgene, Agios, Launch $1B+ Metabolic Immuno-oncology Alliance - GEN News Highlights - GEN". GEN. 
  7. ^ a b "Agios bags $250M in offering as cancer drug speeds toward approval". Boston Business Journal. April 19, 2017.